Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Drug pricing policy stories

Oct 7, 2026

PhRMA sues Trump administration over Medicare drug pricing program

The pharmaceutical industry's main lobbying group filed a lawsuit to block the Trump administration's GLOBE pilot program, which would benchmark US Medicare drug prices to lower international costs. The program aims to test 'most-favored nation' pricing policies.

Oct 7, 2026·3 sources
00
Oct 1, 2026

HRSA approves 10 drugmakers for revised 340B rebate pilot program covering 21 drugs

The Trump administration released a list of 10 pharmaceutical companies, including AbbVie, Merck, and Pfizer, that will be allowed to shift from upfront discounts to after-the-fact rebates on 21 drugs in the 340B drug discount program starting January 1. The revised pilot program includes more manufacturers than the administration's first attempt at a rebate program.

Oct 1, 2026·3 sources
00
Sep 30, 2026

Trump administration finalizes Medicare drug pricing rule with $440 million in savings

CMS finalized the GLOBE demonstration program aimed at matching Medicare drug prices to international rates, but projected savings fell dramatically from $11.9 billion to $440 million after exempting 96% of drugmakers. Only four companies will participate after others signed separate pricing agreements.

Sep 30, 2026·4 sources
00
Sep 28, 2026

Medicare drug price negotiations strain oncology practices despite patient cost relief

The Inflation Reduction Act's Medicare out-of-pocket cap is reducing costs for cancer patients, but community oncology leaders warn that negotiated drug price cuts are creating financial pressures on medical practices.

Sep 28, 2026·2 sources
00
Sep 13, 2026

US Medicare most-favored-nation drug pricing policy could delay launches in lower-price markets

A new modeling study published in The Lancet suggests that US Medicare's most-favored-nation pricing policy, which ties Medicare payments to prices in other high-income countries, could reduce US spending on brand-name drugs but incentivize pharmaceutical companies to increase prices or delay launches in lower-price markets like Europe.

Sep 13, 2026·3 sources
00
Sep 1, 2026

Kenya signs deal with Pfizer to cut cancer drug prices by more than seven times

The Kenyan government has reached an agreement with US pharmaceutical company Pfizer that will reduce the cost of cancer medications by more than sevenfold, according to President William Ruto. The deal is expected to significantly lower treatment costs for cancer patients across the country.

Sep 1, 2026·1 source
00
Aug 26, 2026

White House to announce new drug pricing deals with biotech companies

The Trump administration plans to announce a new round of drug-pricing agreements with several midsized biotech companies on Monday, according to people familiar with the matter.

Aug 26, 2026·2 sources
00
Aug 3, 2026

Sandoz agrees to $450 million settlement with 43 US states over generic drug price-fixing allegations

Swiss generic drugmaker Sandoz has reached a settlement agreement to pay $450 million to 43 US states and territories to resolve antitrust litigation alleging anti-competitive conduct and price manipulation in the generic medicines market. The settlement includes no admission of wrongdoing and will not affect the company's financial guidance.

Aug 3, 2026·9 sources
00
Jul 7, 2026

CMS Proposes Cuts to 340B Drug Pricing Program Payments in 2027 Medicare Rule

The Centers for Medicare & Medicaid Services has proposed cutting Medicare payments for drugs purchased under the 340B Drug Pricing Program in its 2027 rule, reigniting a long-standing dispute between safety-net hospitals and federal regulators over the program designed to help vulnerable populations access medications.

Jul 7, 2026·2 sources
00
Jun 27, 2026

States target pharmacy benefit managers in effort to lower prescription drug prices

Multiple U.S. states are implementing measures to regulate pharmacy benefit management companies that oversee prescription drug coverage for health insurers, as part of efforts to reduce medication costs for consumers.

Jun 27, 2026·2 sources
00
May 18, 2026

Supreme Court Rejects Challenge to Medicare Drug Price Negotiation

The U.S. Supreme Court has rejected a legal challenge to Medicare's drug price negotiation program, a decision that may make remaining pharmaceutical industry lawsuits more difficult to pursue.

May 18, 2026·1 source
00
Apr 4, 2026

Trump Administration Negotiates Drug Pricing Deals with Smaller Pharmaceutical Companies

The White House is negotiating new drug-pricing agreements with smaller biotechnology companies facing the threat of 100% tariffs on imported medicines, according to multiple sources with knowledge of the meetings.

Apr 4, 2026·1 source
00
Feb 6, 2026

Trump Announces Phased Tariff Plan on Generic Drug Imports: 0% Until 2028, Then 100% and 200%

President Donald Trump announced that imported generic drugs will face no tariffs for two years starting August 1, 2026, after which tariffs will rise to 100% in August 2028 and 200% from 2029 onward. The policy aims to encourage domestic pharmaceutical manufacturing but raises concerns about future drug price increases for consumers.

Feb 6, 2026·9 sources
00
Dec 18, 2025

Trump announces all 50 states to participate in Medicaid 'most favored nation' drug pricing program

President Trump announced that all 50 states, Washington D.C., and Puerto Rico have agreed to participate in his administration's 'most favored nation' drug pricing initiative for Medicaid programs, which aims to lower prescription drug costs by tying prices to those paid in other countries.

Dec 18, 2025·6 sources
00

Top claims

  • ▪PhRMA argues in its lawsuit that the Centers for Medicare & Medicaid Services exceeded its statutory authority by using the GLOBE pilot program to rewrite Medicare's pricing structure without congressional action
  • ▪PhRMA General Counsel Jim Stansel stated that the Centers for Medicare & Medicaid Services is replacing Medicare's pricing structure with a system that Congress has declined to implement multiple times over several years
  • ▪CMS's GLOBE rule establishes a "most-favored-nation" pricing system to set hospital drug prices for Medicare Part B patients based on prices paid in comparable overseas countries

People involved

William RutoDonald Trump

Subtopics

Drug Policy, Pricing & Approval13Medication Pricing & Affordability13Healthcare Policy6Medicare & drug pricing policy5Pharma5Drug pricing4FDA regulation & drug policy4Government and Regulatory Policy4Healthcare Access and Insurance4Medicare4Regulatory compliance4US health policy & drug pricing4Drug Classes & Treatment Access3Public healthcare3Trump administration3Drug Approval and Clinical Trials2Generic drugs & biosimilars2Healthcare Costs as Voter Issue2International trade2Medicare policy2Pharmaceutical Industry2Protectionism vs free trade2Tariffs & trade wars2US healthcare regulation2

Related timelines

Trump administration

161 stories

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Russia-Ukraine war

136 stories